Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib

J Thorac Oncol. 2017 Jun;12(6):e78-e80. doi: 10.1016/j.jtho.2017.02.014.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Acrylamides
  • Aged
  • Aniline Compounds
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / chemically induced
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / secondary
  • ErbB Receptors / antagonists & inhibitors*
  • ErbB Receptors / genetics
  • Female
  • Gefitinib
  • Humans
  • Lung Neoplasms / chemically induced
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Mutation
  • Piperazines / adverse effects*
  • Prognosis
  • Quinazolines / therapeutic use*
  • Remission Induction

Substances

  • Acrylamides
  • Aniline Compounds
  • Antineoplastic Agents
  • Piperazines
  • Quinazolines
  • osimertinib
  • EGFR protein, human
  • ErbB Receptors
  • Gefitinib